Upadacitinib for Immune Checkpoint Inhibitor–Related Dermatitis: A Nonrandomized Clinical Trial - Poll - MDSpire

Upadacitinib for Immune Checkpoint Inhibitor–Related Dermatitis: A Nonrandomized Clinical Trial

  • By

  • Chengshui Chen

  • Xinyu Liang

  • Zheng Peng

  • Yan Zou

  • Huijuan He

  • Xiaoyan Zhang

  • Yi He

  • Shixiu Wu

  • May 1, 2026

  • 0 min

Share

Original Source(s)

Upadacitinib for Immune Checkpoint Inhibitor–Related Dermatitis: A Nonrandomized Clinical Trial

  • by Chengshui Chen, Xinyu Liang, Zheng Peng, Yan Zou, Huijuan He, Xiaoyan Zhang, Yi He, Shixiu Wu

  • May 1, 2026

Related Content

Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer

Emerging applications of artificial intelligence for risk stratification in head and neck cancer: a scoping review

Bilateral renal metastasis following radical prostatectomy for prostate cancer: a case report